Adolescent Medicine

Alcohol Abuse

Allergies and Infant Formula

Allergy, Immunology, and ENT

Animal Allergies

Autism

COVID-19

Cardiovascular Diseases

Cardiology

Atopic Dermatitis

Acne

Dermatology

Developmental/Behavioral Disorders

Drug Pipeline News

Emergency Medicine

Diabetes

Diabetes Type 2

Endocrinology

Gastroenterology

Gynecology

Influenza

Antibiotic Resistance

Vaccination and Immunization

Bacterial Conjunctivitis

Vaccines

Infectious disease

Anxiety

Depression

Mental Health

Concussion

Epilepsy

Headache

Neurology

Food Allergies

Obesity

Childhood Obesity

Nutrition

Nutrition News

Neonatal/Perinatology

Obstetrics-Gynecology & Women's Health

Oncology

Pain

Pharmacology

Practice Improvement

ADHD

Antisocial Personality Disorder

Psychiatry

Asthma

Cystic Fibrosis

Pediatric Asthma

Pneumonia

Respiratory

Rheumatoid Arthritis

Sexually Transmitted Diseases

Sexual Health

Skin Diseases

Telemedicine

News 

All News

PNP Corner

AAP Guidelines

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Print Subscription

eNewsletter

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

Joshua Fitch is an editor for Contemporary Pediatrics. 

Articles

Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding. 

FDA warns of drug compounding amid shortages of drugs containing semaglutide

The at-home test correctly identified 98.7% of negative and 92.9% of positive samples for individuals with signs and symptoms of upper respiratory infection, according to a study conducted by the FDA.

FDA grants marketing authorization for Cue OTC, at-home COVID-19 test 

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

Low-dose atropine eye drops may reduce myopia progression in children

Compared to 2017, new HIV infections overall were 12% lower in 2021, falling from approximately 36,500 to 32,100 infections, respectively, according to the CDC. 

CDC: Decline in youth HIV infections drove overall decline in 2021

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics

Facebook

Twitter

LinkedIn

Instagram

Spotlight

2022 Best Tech

Contemporary Pediatrics® Resident Writer Program

Demystifying Infant Formula

Food Insecurity and the Dangers of Infant Formula Dilution

Getting into the Roots of Childhood Atopic Dermatitis

Opt-Out Chlamydia Screening in Adolescent Care

The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants

Update in Pediatric COVID-19 Vaccines

Clinical

View More

1rem

Authors

Frank Ingari is chairman and CEO of Tandigm Health in Conshohocken, Pennsylvania.

A perspective on the Centers for Medicare & Medicaid Services Innovation Center roundtable on health equity.

What does health equity mean?